Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MACK

Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis

Merrimack Pharmaceuticals logo

About Merrimack Pharmaceuticals Stock (NASDAQ:MACK)

Advanced Chart

Key Stats

Today's Range
$15.13
$15.13
50-Day Range
$14.65
$15.13
52-Week Range
$11.53
$15.89
Volume
N/A
Average Volume
396,929 shs
Market Capitalization
$223.77 million
P/E Ratio
1.09
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Stock News Headlines

Merrimack Pharma Stock Price History
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
See More Headlines

MACK Stock Analysis - Frequently Asked Questions

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) posted its quarterly earnings data on Friday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.14.

Merrimack Pharmaceuticals's stock reverse split on the morning of Wednesday, September 6th 2017.The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Merrimack Pharmaceuticals investors own include Rite Aid (RAD), Agenus (AGEN), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Bristol Myers Squibb (BMY) and Meta Platforms (META).

Company Calendar

Last Earnings
5/10/2019
Today
7/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MACK
Previous Symbol
NASDAQ:MACK
CIK
1274792
Employees
426
Year Founded
2000

Profitability

EPS (Trailing Twelve Months)
$13.87
Trailing P/E Ratio
1.09
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$1.18 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1.93%
Return on Assets
-1.78%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.78
Quick Ratio
10.78

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.31 per share
Price / Book
11.55

Miscellaneous

Outstanding Shares
14,790,000
Free Float
10,267,000
Market Cap
$223.77 million
Optionable
Optionable
Beta
1.45

Social Links

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:MACK) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners